Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.
about
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesEarly short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.Progress and challenges in therapies for AIDS in nonhuman primate models.Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responsesSimian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPAVirulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.Susceptibilities of simian immunodeficiency virus to protease inhibitors9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaquesA zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaquesSequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques.Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.Italian consensus statement on paediatric HIV infection.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Tackling HIV and AIDS: contributions by non-human primate models.A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: dose-response curve slope strongly influences class-specific inhibitory potentialPublic Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000).Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus.British HIV Association guidelines for the management of HIV infection in pregnant women 2012
P2860
Q28775900-671331C2-A84D-46BF-96AE-A4E91FA82068Q33643898-A5E55796-90C8-4A72-B178-4B860E3A3234Q33792077-E439C723-05C7-4D48-BE50-E49708F23B5BQ33797464-091D922F-47B1-4A95-BBC5-0EB550524506Q33808891-AF63FA88-4345-415B-8357-BDFB936DD1C5Q33813926-F1CF6112-5275-458D-B2EE-C20B40BD7F0AQ33843148-8A4C8960-9038-4A16-9566-0D6575A43AA9Q33976617-05D1CDA9-E11F-4D03-B8B9-9D6DC5BAC210Q34339657-F1431E72-873C-4A21-BF76-6DD2B8BCBC2AQ34716901-67884F91-B221-43D4-86FA-FC33593473F3Q34939250-B0A9D451-C41C-4529-8A21-B79A5DCB8AA4Q35129347-1A5A65A8-012D-49B6-868E-E7A704EF58E8Q35132138-E06B73C2-9F5F-4D80-9137-1E2E17B0461BQ35752812-B075DD62-C57A-410C-B731-7C06E4E6B127Q35841255-A564EF34-1306-4CE5-A325-55A33AC4C65FQ35984276-8183C303-F8A5-49C9-B2E2-1BF541F8CF86Q37730097-F35633FD-7FE6-40E6-A24B-F35F1DAD55FFQ37761853-7AEFC89A-59A0-4009-A433-C0949687E026Q38325427-CC150C00-A223-4DA9-B9AD-FD9CA630548DQ40191155-7B6DC897-7A8E-433C-B1FB-C5590B3AEA21Q42701528-40E33CE0-0D9A-4A83-86FF-7F9D4F8B5FA9Q43956302-EE6A78CF-66FD-4915-9B88-6C860F1A3336Q45767529-CE093891-14B9-4238-A8FE-B02AD686835BQ57076282-84247201-319E-434A-BE05-01A1CE989B8F
P2860
Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Immediate zidovudine treatment ...... s against rapid onset of AIDS.
@ast
Immediate zidovudine treatment ...... s against rapid onset of AIDS.
@en
type
label
Immediate zidovudine treatment ...... s against rapid onset of AIDS.
@ast
Immediate zidovudine treatment ...... s against rapid onset of AIDS.
@en
prefLabel
Immediate zidovudine treatment ...... s against rapid onset of AIDS.
@ast
Immediate zidovudine treatment ...... s against rapid onset of AIDS.
@en
P2093
P2860
P356
P1476
Immediate zidovudine treatment ...... s against rapid onset of AIDS.
@en
P2093
C J Miller
K K Van Rompay
M B McChesney
M G Otsyula
M L Marthas
N C Pedersen
P2860
P304
P356
10.1128/AAC.39.1.125
P407
P577
1995-01-01T00:00:00Z